Inhibiting the Axl kinase could have applications in both antitumor and antiviral therapy, separate papers published over the past few weeks have reported. In the Jan. 10, 2017, issue of Cell Reports, a team from the French INSERM Institute showed that Axl receptor activity both enabled Zika virus entry into cells and modulated innate immune responses.